drugset / Trial / NCT03184558
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The primary objective is objective response rate.
Timeline
- Start
- 2017-07-26
- Primary completion
- 2018-08-20
- Completion
- 2018-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemcentinib | Small molecule | 200 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |